This inventor holds 1 USPTO granted patent. Top assignee: Jiangsu University. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Xu Zhang - Innovator in Drug Delivery Systems
Introduction
Xu Zhang is a prominent inventor based in Zhenjiang, China. He has made significant contributions to the field of drug delivery systems through his innovative research and development efforts. His work focuses on enhancing the efficacy of drug delivery methods, particularly in targeting tumor cells.
Latest Patents
Xu Zhang holds a patent for a groundbreaking invention titled "Superparamagnetism-modified and neutrophil exosome biomimetic vesicle-based biological preparation for drug delivery, and preparation method thereof." This patent, which falls under the technical field of engineered nanovesicle drug loading systems, describes a method that utilizes superparamagnetism-modified and neutrophil exosome biomimetic vesicles to deliver drugs specifically to tumor cell lines. The preparation method has shown promising results in inducing tumor cell apoptosis and inhibiting tumor growth, significantly extending the survival time of mice and improving the efficacy of cancer treatments.
Career Highlights
Xu Zhang is affiliated with Jiangsu University, where he continues to advance his research in drug delivery systems. His work has garnered attention for its potential applications in cancer therapy, showcasing his commitment to improving patient outcomes through innovative solutions.
Collaborations
Xu Zhang collaborates with notable colleagues, including Hui Qian and Hui Shi, who contribute to his research endeavors. Their combined expertise enhances the development of effective drug delivery systems.
Conclusion
Xu Zhang's innovative work in drug delivery systems exemplifies the potential of engineering to address critical challenges in cancer treatment. His contributions are paving the way for more effective therapies that can significantly improve patient survival rates.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile